Cisplatin-induced ecDNA enhances tumor malignancy and accelerates chemoresistance acquire in gastric cancer.
This study revealed that cisplatin could promote ecDNA generation, which enhanced malignant phenotypes, including cell proliferation, motility and drug resistance, and was associated with poorer patient prognosis, and targeting ecDNA with inhibitors could reverse these effects.